Work

A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL).

Year: 2006

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v108.11.1862.1862

Authors: Oliver Ottmann, Hagop Kantarjian, Richard Larson, Philipp le Courte, Michele Baccarani, Teresa Rafferty, Aaron Weitzman, Francis Giles

Institutions: Goethe University Frankfurt, The University of Texas MD Anderson Cancer Center, University of Chicago, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Novartis (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2589116019

FWCI: 3.206

Cites:

Cited by: 19

Related to: 10